# Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model

> **NCT01527188** · PHASE2 · COMPLETED · sponsor: **Stallergenes Greer** · enrollment: 355 (actual)

## Conditions studied

- Allergic Rhinitis Due to House Dust Mite

## Interventions

- **DRUG:** 100 IR house dust mites allergen extract tablet
- **DRUG:** 300 IR house dust mites allergen extract tablet
- **DRUG:** 500 IR house dust mites allergen extract tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT01527188
- **Lead sponsor:** Stallergenes Greer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-09-19
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01527188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01527188, "Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01527188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*